NCT06022289 2023-09-01
Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors
Tianjin Medical University Second Hospital
Phase 2 Unknown
Clinical Trials
10 trialsNCT03810339 2023-06-27
Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Sun Yat-sen University
Phase 2 Unknown
NCT05528406 2022-09-06
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation
Shanghai Henlius Biotech
Phase 2 Unknown
NCT05512780 2022-08-23
Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage â…¡-â…¢ HR-positive/HER2-negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT05274191 2022-03-10
An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors
Zhongshan Hospital Xiamen University
Phase 2 Unknown
NCT05097781 2021-10-28
Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients
Ruijin Hospital
Phase 2 Unknown
NCT04832204 2021-04-05
Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
Beijing Hospital
Phase 2 Unknown
NCT04569916 2020-09-30
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT04179656 2019-11-27
The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT02255292 2014-10-02
A Study: Pure CBD as Single-agent for Solid Tumor.
Hadassah Medical Organization
Phase 2 Unknown